Skip to content
Inciteful Med

Treatment & Management: Living Bleed-Free

Last updated:

Factor XIII deficiency is primarily treated with monthly prophylactic IV injections of clotting factor concentrates (Corifact or Tretten) to prevent spontaneous bleeding. Due to the factor's long half-life, treatments are infrequent and can often be administered at home via a quick push injection.

Key Takeaways

  • • Prophylaxis (preventative treatment) is the standard of care to prevent life-threatening spontaneous bleeds.
  • • Factor XIII has a long half-life, allowing for convenient monthly dosing schedules.
  • • Treatments are given via a quick 2-5 minute IV push, often administered at home.
  • • Two main concentrates exist: plasma-derived Corifact and recombinant Tretten.
  • • Routine monitoring ensures trough levels stay above 15% for effective protection.

Managing Factor XIII (FXIII) deficiency has been transformed by modern medicine. Because the risk of spontaneous, life-threatening bleeding—especially in the brain—is so high in severe cases, the goal of treatment is prophylaxis (preventative treatment) to stop bleeding before it ever starts [1][2][3].

The Advantage of “Half-Life”

The term half-life simply means the time it takes for half of the medicine to leave your body. Factor XIII has a uniquely long half-life, lasting much longer in the system than most other clotting factors [4]. Because it can take 11 to 14 days for half of the factor to leave your blood, most patients only need treatment once every 4 weeks (monthly) [5][6]. This means fewer needles and a life that feels much less “medical” [2].

How Treatment is Given

Factor XIII is given as an intravenous (IV) injection, meaning it goes directly into a vein. Unlike some other medical treatments that require sitting for hours with an IV drip, Factor XIII is a “push” injection [7].

  • Speed: The actual injection usually takes only 2 to 5 minutes to complete.
  • Home Infusion: Most families eventually transition to “home infusion.” This means you or a family member can learn to give the medicine at home, or a nurse can come to your house, avoiding monthly trips to the hospital or clinic [2].

Modern Treatment Options

There are two main types of Factor XIII concentrates. Your doctor will choose one based on your specific deficiency subtype.

  • Corifact (or Fibrogammin): This is a plasma-derived concentrate made from human blood [8]. It contains both Subunit A and Subunit B. It is used for both types of deficiency and is the only option for those with Subunit B deficiency [9][10].
  • Tretten: This is a recombinant factor manufactured in a lab without human blood [10]. It contains only Subunit A. It is used for Subunit A deficiency and carries zero risk of blood-borne infections [2][7].

Why We Avoid “Rescue” Treatments

In the past, patients were treated with Cryoprecipitate or Fresh Frozen Plasma (FFP). Today, these are only used in emergencies if modern concentrates are unavailable [11]. Modern concentrates are much safer because they undergo purification to remove viruses, and they allow for very precise dosing in a small volume, which is easier on the heart and lungs [7][12].

Dosing and Monitoring

The typical dose is 35 IU/kg every 4 weeks, though your doctor may adjust this (ranging from 10 to 50 IU/kg) [2][13].

To ensure the treatment is working, doctors measure your trough level—the amount of factor left in your blood right before your next dose. Most experts recommend keeping this level above 15% (0.15 IU/mL) to prevent spontaneous bleeds [14]. For pregnant women, keeping levels above 10% is critical to preventing miscarriage [15][16]. Your care team will also check for inhibitors (antibodies) to make sure your body isn’t working against the medicine [17][3].

Frequently Asked Questions

What is the goal of Factor XIII treatment?
The main goal is prophylaxis, which means giving regular preventative treatments to stop spontaneous bleeding before it starts. This is critical because severe cases carry a high risk of life-threatening bleeding, particularly in the brain.
How often do I need treatment for Factor XIII deficiency?
Most patients only need treatment once every 4 weeks (monthly). This is possible because Factor XIII has a long half-life, meaning it stays in the blood for 11 to 14 days before wearing off.
What is the difference between Corifact and Tretten?
Corifact is a plasma-derived concentrate used for both Subunit A and B deficiencies. Tretten is a recombinant (lab-made) product that carries zero viral risk but is only used for Subunit A deficiency.
Can I take Factor XIII treatment at home?
Yes, most families eventually transition to home infusion. Because the injection is a quick 'push' that takes only 2 to 5 minutes, you or a family member can learn to administer it at home, or a nurse can visit you.
What is a trough level and why does it matter?
A trough level is the amount of factor remaining in your blood right before your next dose. Doctors recommend keeping this level above 15% to ensure you are protected from spontaneous bleeds throughout the month.

Questions for Your Doctor

  • • Which medication is best for my specific deficiency: Tretten or Corifact?
  • • Can you help us transition to 'Home Infusion' so we don't have to come to the hospital every month?
  • • What is the exact 'trough' level you want me to maintain?
  • • How long should it take to 'push' my dose of Factor XIII?
  • • In an emergency, what is my 'on-demand' dose?

Questions for You

  • • Am I comfortable learning how to give an IV injection at home, or would I prefer a home nurse to help?
  • • Do I notice more bruising or fatigue in the few days just before my next scheduled dose?
  • • How am I keeping track of my infusion dates and any minor bleeding episodes?

Want personalized information?

Type your question below to get evidence-based answers tailored to your situation.

References

  1. 1

    Congenital factor XIII deficiency caused by F13A1 gene mutations presenting with intracranial hemorrhage: a case report.

    Wang H, Yang R, Li J

    Frontiers in pediatrics 2025; (13()):1732065 doi:10.3389/fped.2025.1732065.

    PMID: 41488895
  2. 2

    Recombinant factor XIII prophylaxis is safe and effective in young children with congenital factor XIII-A deficiency: international phase 3b trial results.

    Kerlin BA, Inbal A, Will A, et al.

    Journal of thrombosis and haemostasis : JTH 2017; (15(8)):1601-1606 doi:10.1111/jth.13748.

    PMID: 28581691
  3. 3

    Safety and effectiveness of recombinant factor XIII-A2 in congenital factor XIII deficiency: Real-world evidence.

    Poulsen LH, Kerlin BA, Castaman G, et al.

    Research and practice in thrombosis and haemostasis 2022; (6(2)):e12628 doi:10.1002/rth2.12628.

    PMID: 35243202
  4. 4

    Factor XIII topology: organization of B subunits and changes with activation studied with single-molecule atomic force microscopy.

    Protopopova AD, Ramirez A, Klinov DV, et al.

    Journal of thrombosis and haemostasis : JTH 2019; (17(5)):737-748 doi:10.1111/jth.14412.

    PMID: 30773828
  5. 5

    Real-Life Population Pharmacokinetics of Recombinant Factor XIII and Dosing Considerations for Preventing the Risk of Bleeding in Patients with FXIII Congenital Deficiency.

    Cojutti PG, Zanon E, Pasca S, et al.

    Clinical pharmacokinetics 2022; (61(4)):505-513 doi:10.1007/s40262-021-01079-x.

    PMID: 34718987
  6. 6

    Recombinant FXIII (rFXIII-A2) Prophylaxis Prevents Bleeding and Allows for Surgery in Patients with Congenital FXIII A-Subunit Deficiency.

    Carcao M, Altisent C, Castaman G, et al.

    Thrombosis and haemostasis 2018; (118(3)):451-460 doi:10.1055/s-0038-1624581.

    PMID: 29448295
  7. 7

    Successful perinatal management of a woman with congenital factor XIII deficiency using recombinant factor XIII: A case report and literature review.

    Ito Y, Tsuji S, Kasahara M, et al.

    The journal of obstetrics and gynaecology research 2024; (50(2)):262-265 doi:10.1111/jog.15819.

    PMID: 37875278
  8. 8

    Reciprocal stabilization of coagulation factor XIII-A and -B subunits is a determinant of plasma FXIII concentration.

    Byrnes JR, Lee T, Sharaby S, et al.

    Blood 2024; (143(5)):444-455 doi:10.1182/blood.2023022042.

    PMID: 37883802
  9. 9

    Long Term Follow up Study on a Large Group of Patients with Congenital Factor XIII Deficiency Treated Prophylactically with Fibrogammin P®.

    Naderi M, Karimi M, Hosseini MS, et al.

    Iranian journal of pharmaceutical research : IJPR 2016; (15(2)):635-40.

    PMID: 27642336
  10. 10

    Developing the First Recombinant Factor XIII for Congenital Factor XIII Deficiency: Clinical Challenges and Successes.

    Carcao M, Fukutake K, Inbal A, et al.

    Seminars in thrombosis and hemostasis 2017; (43(1)):59-68 doi:10.1055/s-0036-1585076.

    PMID: 27556350
  11. 11

    Delayed and prolonged umbilical stump bleeding in a Caucasian newborn as a presenting feature of factor XIII deficiency.

    Lim DBN, Mangles S, Goturu A

    BMJ case reports 2022; (15(10)) doi:10.1136/bcr-2022-248743.

    PMID: 36207057
  12. 12

    Recombinant factor XIII A-subunit in a patient with factor XIII deficiency and recurrent pregnancy loss.

    Al-Khabori M, Pathare A, Menegatti M, Peyvandi F

    Journal of thrombosis and haemostasis : JTH 2018; (16(6)):1052-1054 doi:10.1111/jth.14126.

    PMID: 29665207
  13. 13

    A large case series on surgical outcomes in congenital factor XIII deficiency patients in Iran.

    Naderi M, Haghpanah S, Miri-Aliabad G, et al.

    Journal of thrombosis and haemostasis : JTH 2017; (15(12)):2300-2305 doi:10.1111/jth.13872.

    PMID: 29028293
  14. 14

    Minimal factor XIII activity level to prevent major spontaneous bleeds.

    Menegatti M, Palla R, Boscarino M, et al.

    Journal of thrombosis and haemostasis : JTH 2017; (15(9)):1728-1736 doi:10.1111/jth.13772.

    PMID: 28688221
  15. 15

    Congenital factor XIII deficiency: comprehensive overview of the FranceCoag cohort.

    Bouttefroy S, Meunier S, Milien V, et al.

    British journal of haematology 2020; (188(2)):317-320 doi:10.1111/bjh.16133.

    PMID: 31414482
  16. 16

    Treatment with Recombinant Factor XIII (Tretten) in a Pregnant Woman with Factor XIII Deficiency.

    Abdel-Samad N

    The American journal of case reports 2017; (18()):436-439 doi:10.12659/ajcr.901502.

    PMID: 28432284
  17. 17

    Comparison of F13A1 gene mutations in 73 patients treated with recombinant FXIII-A2.

    Ivaškevičius V, Biswas A, Garly ML, Oldenburg J

    Haemophilia : the official journal of the World Federation of Hemophilia 2017; (23(3)):e194-e203 doi:10.1111/hae.13233.

    PMID: 28520207

This guide explains treatment options for Factor XIII deficiency for educational purposes only. Always consult your hematologist for dosing instructions and treatment decisions specific to your condition.

Stay up to date

Get notified when new research about Factor XIII Deficiency is published.

No spam. Unsubscribe anytime.